2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 125

Implementation of a Bone Health Team Markedly Improves Osteoporosis Screening, Diagnosis and Treatment Initiation Rates Compared to Standard Primary Care Practice

Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

9:00AM-11:00AM: Abstract Number: 141

Improved Follow-up of Hypertension in Rheumatology Patients: Results of a Pilot

Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

9:00AM-11:00AM: Abstract Number: 877

Improved Survival in Granulomatosis with Polyangiitis: A Population-Based Study

Vasculitis Poster I

9:00AM-11:00AM: Abstract Number: 561

Improvement in Disease Activity and the Long-Term Risk of Serious Infectious Events in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 699

Improving Ankylosing Spondylitis Specific Outcomes at 6 Months Utilising a Novel Self-Management Education Program

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 509

In Early Undifferentiated Polyarthritis, 14-3-3η Seroreversion or Sustained Negativity Is Associated with Better Radiographic Outcomes, Even in DAS-28 Remitters

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 519

In Indigenous North Americans at High Risk for RA Complement C5 Level Is Associated with ACPA Positivity and C5a with Transition to Synovitis Even after Correcting for in Vitro Complement Activation Found with Prolonged Sample Storage

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 792

Incidence and Persistence of Cervical Human Papillomavirus Infection in Mexican Systemic Lupus Erythematosus Women

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 850

Incidence and Predictors of Severe Heart Disease in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 369

Incidence of Fragility Hip Fractures over 10 Years (2004-13) in Three UK Centres with Reference to Local Fracture Prevention (‘fracture liaison’) Service Activity

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 348

Incidence Rate of Potential Osteonecrosis of the Jaw Among Women with Postmenopausal Osteoporosis Treated with Prolia or Bisphosphonates

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 816

Incomplete Tolerance in Anergic B Cells in SLE: T Helper Signals Restore B Cell Receptor Signaling in Autoreactive Anergic B Cells By Upregulating CD45 Phosphatase Activity

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 243

Increase in Risk of Future Attacks in Patients with Incident Gout: A Population-Based Study over 20 Years

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 536

Increased Circulating CD14brightCD16+ Intermediate Monocytes Are Regulated By TNF-Alpha and IL-6 Axis in Accompany with Disease Activity in Rheumatoid Arthritis Patients

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 55

Increased Incidence of Tuberculosis Among Systemic Lupus Erythematous Patients – Should Tuberculosis Screening at Diagnosis be the Next Step?

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].